 |
|
New study finds advanced liver cancer patients live longer by taking anti-cancer drug sorafenib
July 24, 2008Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug. The findings, published in the July 23rd, 2008 issue of the New England Journal of Medicine, is a significant advance in the management of liver cancer, which is the third cause of cancer death globally, often resulting in death within a year of diagnosis.
"This is the first time that we've had an effective systemic treatment for liver cancer," said Josep Llovet, MD, Director of Research in Liver Cancer at Mount Sinai School of Medicine in New York, and a Professor at the Barcelona Clinic Liver Cancer (BCLC) Group in Barcelona, Spain and lead author of the study. "Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful."
Sorafenib, a tablet that is taken orally, is approved in the United States for treating a form of advanced kidney cancer, and is currently being evaluated in patients with other cancers. Some 40 percent of liver cancers (and up to 80 percent in Asia and sub-Saharan Africa) are diagnosed at an advanced stage. Therapy for advanced liver cancer may include surgery (if possible), radiation therapy and/or regional chemotherapy (delivered directly into the liver). However, no systemic treatment-anti-cancer medication that enters the bloodstream, either as an oral or intravenous medicine-has proven effective to date for advanced liver cancer.
Dr. Llovet and his associates examined overall survival and the time it took for cancer to grow among patients with previously untreated liver cancer who were randomly assigned to receive either 400 mg of sorafenib twice daily (299 patients) or a placebo (303 patients).
Patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to the positive findings, the study was terminated early.
The incidence of adverse side effects was similar between the two groups (52 percent in the sorafenib group and 54 percent for placebo). The most common moderate to serious side effects were diarrhea (11 percent vs. 2 percent), skin reactions in the hands and feet (8 percent vs. 1 percent), fatigue (10 percent vs. 15 percent) and bleeding (6 percent vs. 9 percent).
The Mount Sinai Hospital / Mount Sinai School of Medicine
Dr. Llovet and his associates examined overall survival and the time it took for cancer to grow among patients with previously untreated liver cancer who were randomly assigned to receive either 400 mg of sorafenib twice daily (299 patients) or a placebo (303 patients).
Patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to the positive findings, the study was terminated early.
The incidence of adverse side effects was similar between the two groups (52 percent in the sorafenib group and 54 percent for placebo). The most common moderate to serious side effects were diarrhea (11 percent vs. 2 percent), skin reactions in the hands and feet (8 percent vs. 1 percent), fatigue (10 percent vs. 15 percent) and bleeding (6 percent vs. 9 percent).
The Mount Sinai Hospital / Mount Sinai School of Medicine
Liver Cancer Current Events and Liver Cancer News RSSResearchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Toward explaining why hepatitis B hits men harder than women
Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.
Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.
1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."
Parasite growth hormone pushes human cells to liver cancer
Scientists have found that the human liver fluke (Opisthorchis viverrini) contributes to the development of bile duct (liver) cancer by secreting granulin, a growth hormone that is known to cause uncontrolled growth of cells.
Certain cancers more common among HIV patients than non-HIV patients
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
Discovery could improve hepatitis C treatment
Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.
Sorafenib significantly improves the length of time before breast cancer worsens
ne of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.
Penn State College of Medicine research isolates liver cancer stem cells prior to tumor formation
Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.
New biomarker predicts response to hepatitis C treatment
Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference.
More Liver Cancer Current Events and Liver Cancer News Articles
 |
100 Q&A About Liver Cancer, Second Edition (100 Questions & Answers about . . .) by Ghassan Abou-Alfa (Author), Ronald DeMatteo (Author) EMPOWER YOURSELF! Whether you're a newly diagnosed liver cancer patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor's and patient's/caregiver's views, 100 Questions & Answers About Liver Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a medical oncologist and a gastrointestinal surgeon, with actual patient/caregiver commentary, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. |
 |
Cancer Be Gone Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed". |
 |
FlameEz-Liver, 60 Capsules/Bottle by FlameEz There are many types of liver disease. Whether the liver is infected with a virus or injured by chemicals, the process of the liver damage always involves inflammation. If properly treated, the inflammation may go away and the liver can heal itself. If left untreated, the inflamed liver will start to scar. As excess scar tissue grows, it replaces healthy liver tissue and leads to fibrosis or cirrhosis. Although it is important to treat the liver disease in the inflammation and fibrosis stages, the treatment choice is limited because many drugs are metabolized by the liver and a few drugs that are used routinely to treat liver disease have significant side effects. Natural remedies are available as alternative approach for liver disease. FlameEz-Liver is a high quality natural liver... |
 |
Liver Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science) by Tamra B. Orr (Author) |
 |
Liver Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Liver Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Liver Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Liver Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Cure Hepatocellular (Liver) Cancer Sweatshirt X-Large White by Shop Zeus |
|
Ali (Follow a young girl's battle with a rare form of liver cancer) Also With: Aquarius Health Care Video (Primary Contributor) | |
 |
Fight Against Hepatocellular (Liver) Cancer Mug by Design a Product LLC Text on mug: Fight Against Hepatocellular (Liver) Cancer * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
|
Surgsat: Professional Video Journal in General Surgery Volume II: 11:21 Liver Resection for Hepatocellular Carcinoma, 11:22 Operative Treatment of Cancer of the Colon, 11:23-24 The Technique of Total Thyroidectomy c1986 Video tape. John L. Cameron, M.D., editor. The John Hopkins Medical Institutions. CME-SAT. | |
 |
DANGER MDA MAY CAUSE CANCER LIVER TOXIN AUTHORIZED PERSONNEL ONLY RESPIRATORS AN by Accuform Signs ADHESIVE DURA VINYL (XV) Dual-layered Adhesive Dura Vinyl delivers exceptional flexibility and performance. Durability, even in the toughest indoor and outdoor conditions.Material Features: High-gloss over-laminate film is bonded to printed image. Sub-surface legend protected from water, chemicals and abrasion. Flexible, 6-mil thick vinyl. Permanent acrylic adhesive backing. Service temperature range: -20°F to 140°F. Durability: 5-7 years outdoors. Square corners without holes; scored backing for quick peel-off and application. |
| © 2009 BrightSurf.com |